Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access to SU011248 (sunitinib / Sutent) for metastatic renal cell carcinoma
2005-002097-30Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Pfizer. Primary endpoints: Access to SU011248 treatment and Clinical outcomes (exploratory). Started Jun 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2005-002097-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002097-30.